Recent Quotes (30 days)

You have no recent quotes
chg | %

Oncolytics Biotech Inc.  

(Public, TSE:ONC)   Watch this stock  
Find more results for ONC
-0.010 (-1.69%)
Oct 19 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.58 - 0.60
52 week 0.19 - 1.13
Open 0.60
Vol / Avg. 29,903.00/241,000.00
Mkt cap 80.87M
P/E     -
Div/yield     -
EPS -0.13
Shares 139.43M
Beta 1.07
Inst. own     -
Aug 10, 2017
Oncolytics Biotech Inc at Canaccord Genuity Growth Conference

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -123.71% -71.85%
Return on average equity -161.95% -85.62%
Employees 21 -
CDP Score - -


1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7
+1-403-6707380 (Phone)
+1-403-2830858 (Fax)

Website links


Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

Officers and directors

Wayne F. Pisano Chairman of the Board
Matthew C. Coffey Ph.D. President, Chief Executive Officer, Chief Operating Officer, Director
Kirk J. Look Chief Financial Officer
George M. Gill M.D. Senior Vice President - Regulatory Affairs & Chief Safety Officer
Mary Ann Dillahunty J.D. Vice President - Intellectual Property
Andres A. Gutierrez M.D., PhD. Chief Medical Officer
Alan J. Tuchman M.D. Chief Neuro Oncology Research Officer
Age: 69
Angela Frances Holtham Director
Edwin Levy Ph.D. Director
J. Mark Lievonen Director